Aclidinium bromide is a competitive, selective muscarinic receptor antagonist (also known as an anticholinergic), with a longer residence time at the M3 receptors than the M2 receptors. M3 receptors mediate contraction of airway smooth muscle. Inhaled aclidinium bromide acts locally in the lungs to antagonise M3 receptors of airway smooth muscle and induce bronchodilation.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Aclidinium bromide is the active ingredient of these drugs:
Australia Austria Ireland Lithuania Netherlands
Austria Cyprus Hong Kong Ireland Lithuania
Aclidinium bromide is also found within below combination drugs:
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):